SG11201805000RA - Method of photodynamic therapy (pdt) for bladder cancer - Google Patents

Method of photodynamic therapy (pdt) for bladder cancer

Info

Publication number
SG11201805000RA
SG11201805000RA SG11201805000RA SG11201805000RA SG11201805000RA SG 11201805000R A SG11201805000R A SG 11201805000RA SG 11201805000R A SG11201805000R A SG 11201805000RA SG 11201805000R A SG11201805000R A SG 11201805000RA SG 11201805000R A SG11201805000R A SG 11201805000RA
Authority
SG
Singapore
Prior art keywords
international
bladder cancer
photodynamic therapy
pdt
oslo
Prior art date
Application number
SG11201805000RA
Other languages
English (en)
Inventor
Kjetil Hestdal
Aslak Godal
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of SG11201805000RA publication Critical patent/SG11201805000RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/307—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the urinary organs, e.g. urethroscopes or cystoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11201805000RA 2015-12-17 2016-12-19 Method of photodynamic therapy (pdt) for bladder cancer SG11201805000RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200938 2015-12-17
PCT/EP2016/081809 WO2017103285A1 (en) 2015-12-17 2016-12-19 Method of photodynamic therapy (pdt) for bladder cancer

Publications (1)

Publication Number Publication Date
SG11201805000RA true SG11201805000RA (en) 2018-07-30

Family

ID=55066354

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805000RA SG11201805000RA (en) 2015-12-17 2016-12-19 Method of photodynamic therapy (pdt) for bladder cancer

Country Status (18)

Country Link
US (2) US11235168B2 (enExample)
EP (1) EP3389716B1 (enExample)
JP (1) JP6995755B2 (enExample)
KR (1) KR102787192B1 (enExample)
CN (2) CN119345612A (enExample)
AU (1) AU2016372575B2 (enExample)
BR (1) BR112018011965A2 (enExample)
CA (1) CA3008552C (enExample)
CL (1) CL2018001612A1 (enExample)
DK (1) DK3389716T3 (enExample)
ES (1) ES2910034T3 (enExample)
IL (1) IL259925B (enExample)
MX (1) MX385912B (enExample)
PL (1) PL3389716T3 (enExample)
RU (1) RU2745194C2 (enExample)
SG (1) SG11201805000RA (enExample)
WO (1) WO2017103285A1 (enExample)
ZA (1) ZA201804530B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3389716B1 (en) * 2015-12-17 2022-03-23 Photocure ASA Method of photodynamic therapy (pdt) for bladder cancer
CN110420326A (zh) * 2019-09-17 2019-11-08 上海复旦张江生物医药股份有限公司 一种多替泊芬的应用
KR20240011794A (ko) * 2021-08-17 2024-01-26 보스톤 싸이엔티픽 싸이메드 인코포레이티드 광활성제의 활성화를 위한 디바이스, 시스템 및 방법
KR20250154511A (ko) 2023-03-07 2025-10-28 포토큐어 에이에스에이 방광암 치료
WO2026052815A1 (en) 2024-09-05 2026-03-12 Photocure Asa Use of hal in a method for predicting bladder cancer immunotherapy response

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US20050003154A1 (en) * 2002-12-13 2005-01-06 White Gary L. Laminated building panels having preselected colors
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
GB0700580D0 (en) 2007-01-11 2007-02-21 Photocure Asa Use
GB0724279D0 (en) 2007-12-12 2008-01-23 Photocure Asa Use
CN101891639A (zh) 2009-05-20 2010-11-24 上海先导化学有限公司 一种制备5-氨基酮戊酸盐酸盐的方法
AU2010257752B2 (en) 2009-06-11 2015-04-09 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
WO2010142457A1 (en) 2009-06-11 2010-12-16 Photocure Asa Semi-solid compositions and pharmaceutical products
RU2448745C2 (ru) * 2010-05-31 2012-04-27 Олег Феликсович Каган Способ лечения поверхностного рака мочевого пузыря
US20150088001A1 (en) 2011-12-19 2015-03-26 Technical University Of Denmark Illumination System for Endoscopic Applications
RU2635563C2 (ru) * 2012-08-03 2017-11-14 ФотоКьюэр АСА Соединения
GB201221123D0 (en) * 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
EP3389716B1 (en) * 2015-12-17 2022-03-23 Photocure ASA Method of photodynamic therapy (pdt) for bladder cancer

Also Published As

Publication number Publication date
US11235168B2 (en) 2022-02-01
CL2018001612A1 (es) 2019-01-11
RU2745194C2 (ru) 2021-03-22
AU2016372575A1 (en) 2018-07-12
CA3008552A1 (en) 2017-06-22
DK3389716T3 (da) 2022-04-11
MX385912B (es) 2025-03-18
ES2910034T3 (es) 2022-05-11
IL259925A (en) 2018-07-31
CN119345612A (zh) 2025-01-24
KR102787192B1 (ko) 2025-03-25
KR20180094986A (ko) 2018-08-24
PL3389716T3 (pl) 2022-06-20
AU2016372575B2 (en) 2022-12-08
EP3389716A1 (en) 2018-10-24
JP2019501161A (ja) 2019-01-17
NZ743697A (en) 2024-10-25
ZA201804530B (en) 2019-09-25
EP3389716B1 (en) 2022-03-23
RU2018123834A3 (enExample) 2020-04-13
US11980772B2 (en) 2024-05-14
JP6995755B2 (ja) 2022-01-17
BR112018011965A2 (pt) 2018-12-04
US20220152411A1 (en) 2022-05-19
RU2018123834A (ru) 2020-01-17
CA3008552C (en) 2024-01-02
WO2017103285A1 (en) 2017-06-22
US20190022404A1 (en) 2019-01-24
CN108697800A (zh) 2018-10-23
IL259925B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201909019SA (en) Methods of treatment using a jak inhibitor compound
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901501UA (en) Compositions and methods for enhancing cancer radiotherapy
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201803728YA (en) Topical pharmaceutical formulations for treating inflammatory-related conditions
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201907505TA (en) Low-viscosity, high-concentration evolocumab formulations and methods of making the same
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201805001UA (en) Method of treating influenza a
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same